Nonin Medical Announces United Kingdom and Ireland Distribution Agreement with Terumo Cardiovascular Group in Europe for Nonin's

Nonin Medical Announces United Kingdom and Ireland Distribution Agreement with
Terumo Cardiovascular Group in Europe for Nonin's SenSmart™ Universal Oximetry
                                    System

PR Newswire

MINNEAPOLIS, Jan. 28, 2014

MINNEAPOLIS, Jan. 28, 2014 /PRNewswire/ -- Nonin Medical, a leader in
noninvasive medical monitoring, today announced that it has entered into a
multi-year distribution agreement with Terumo Cardiovascular Group in Europe.
As of January 2014, Terumo Cardiovascular Group will distribute Nonin's
SenSmart™ Universal Oximetry System to all hospitals in the UK and Ireland. A
similar distribution agreement between the two companies for the United States
was announced in April 2013.Terumo manufactures and markets medical devices
for the global cardiac surgery market.

(Photo: http://photos.prnewswire.com/prnh/20140128/CG54340)

The Nonin SenSmart Universal Oximetry System is the first dedicated oximeter
system that provides measurements of both regional oximetry (rSO[2]) and pulse
oximetry (SpO[2]). While providing industry-leading rSO[2] accuracy,* the
SenSmart system provides comprehensive monitoring of up to six-channels of
rSO[2] and SpO[2] monitoring. No other oximeter system provides more than four
channels of monitoring. The signal processor is substantially smaller than
previous versions, making the SenSmart system ideal for use in a variety of
settings where space is an issue, such as neonatal incubators. The system
allows anesthesiologists, perfusionists, cardiovascular surgeons,
neonatologists, intensivists, and other clinicians to quickly react to reverse
tissue ischemia events before they become critical.

"Nonin Medical is pleased that this agreement, which takes advantage of
Terumo's extensive cardiovascular relationships in heart hospitals in the UK
and Ireland, will accelerate the adoption of the SenSmart System in the UK and
Ireland," said Chris Holland, Vice President of Business Development for Nonin
Medical. "Nonin's SpO[2] and rSO[2] technologies are cost-effective monitoring
tools that help aid clinicians in caring for their patients with early
detection of potentially dangerous events."

"Terumo UK is extremely excited about this collaboration with Nonin Medical
and the opportunity it provides to both our current and new customers by
adding their state-of-the-art regional oximetry to our current range of inline
patient monitoring technologies," said Terumo UK Branch Manager Graham Walker.
"We believe that this new addition to our product portfolio will be seen as a
further indication of our commitment to provide the latest technology
available to the UK cardiovascular market."

Cardiovascular surgery is a common procedure in the UK and Ireland. Regional
oximetry-monitored procedures typically allow for early indication of oxygen
desaturation that could lead to stroke, neurocognitive decline and other
neurological or major organ injuries resulting from inadequate oxygen
saturation. Regional oximetry solutions have been shown to reduce the cost of
post-operative care and improve patient outcomes.^1

Advantages of the SenSmart Universal Oximetry System include:

  oVersatile: The SenSmart system provides clinicians the ability to use
    Nonin SenSmart-compatible rSO[2] sensors and/or SpO[2] sensors to monitor
    up to six sites on neonatal, pediatric and adult patients.
  oHighly Accurate: The SenSmart System's EQUANOX™ Advance rSO[2] Sensor
    provides clinicians with state-of-the-art accuracy. Nonin's reusable
    SpO[2] Soft Sensors provide fast, accurate and reliable readings even in
    patients with low perfusion or in the presence of motion.
  oEasy to Use: The smaller, lighter and less-intrusive SenSmart Universal
    Signal Processors automatically recognize and display either the rSO[2] or
    SpO[2] signal, as well as the colored channel number you have chosen to
    connect to.
  oConvenient: The portable, easy-to-operate SenSmart Monitor offers
    Bluetooth® wireless connectivity and comes with SenSmart Download
    Software.
  oPediatric-Specific Spacing of Light Emitters and Detectors: Designed
    specifically for patients weighing less than 40 kg with varying levels of
    myelination.

For more information about the Nonin SenSmart System, visit www.sensmart.com.

About Nonin Medical, Inc.

Nonin Medical, Inc. invented the finger pulse oximeter and designs and
manufactures noninvasive medical monitoring solutions that meet customers'
technology needs today and tomorrow. Headquartered in Minneapolis, Minn., with
a customer center in Amsterdam, the Netherlands, Nonin Medical sells its pulse
and regional oximeters, capnographs, sensors and software to health
professionals and consumers in more than 125 countries. The company also has
more than 200 OEM partners worldwide. For more information, visit
www.nonin.com.

About Terumo Europe Cardiovascular Systems

Terumo Europe Cardiovascular Systems is an integral part of the Terumo's
family of cardiovascular businesses and is committed to developing innovative
technologies for the treatment of cardiovascular disease. In Europe, Terumo
Cardiovascular Systems provides products and service such as Capiox®
Oxygenators, customized Tubing Sets, CDI® Blood Parameter Monitoring System,
Pall® filter brand products, VirtuoSaph Plus®, the Endoscopic Vein Harvesting
System. For more information, visit www.terumo-europe.com.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device
manufacturers with $5 billion in sales and operations in more than 160
nations. Founded in 1921, the company develops, manufactures, and distributes
world-class medical devices including products for use in cardiothoracic
surgery, interventional procedures, and transfusion medicine; the company also
manufactures a broad array of syringe and hypodermic needle products for
hospital and physician office use. Terumo contributes to society by providing
valued products and services to the healthcare market and by responding to the
needs of healthcare providers and the people they serve.

* Accuracy data based on 8004CA sensor clinical results.

Reference:

1. Goldman SM, Sutter FP, Wertan MA, et al. Outcome improvement and cost
reduction in an increasingly morbid cardiac surgery population. Semin
Cardiothorac Vasc Anesth 2006;10:171-5.

©2014 Terumo Cardiovascular Systems Corporation. Terumo® is a trademark of
Terumo Corporation. SenSmart™ and EQUANOX™ are trademarks of Nonin Medical,
Inc. Bluetooth® is a trademark of Bluetooth SIG.

SOURCE Nonin Medical, Inc.

Website: http://www.nonin.com
Website: http://www.terumo-europe.com
Contact: Jessica Herczeg, Terumo Cardiovascular Group, Phone: +49 (0) 6196
8023 538, jessica.herczeg@terumo-europe.com, www.terumo-europe.com, or Melanie
Stanek, Director, Corporate Communications, Nonin Medical, Inc., Phone: +1 612
804 7714, melanie.stanek@nonin.com, www.noninequanox.com/news
 
Press spacebar to pause and continue. Press esc to stop.